Humacyte, Inc. reports commercial, clinical and regulatory developments for its bioengineered human tissue platform. The company’s first FDA-approved product, Symvess, is an acellular tissue engineered vessel indicated for treatment of extremity vascular trauma, while other ATEV applications remain part of its broader regenerative medicine pipeline.
Recurring updates include Symvess commercialization, hospital access and distribution arrangements, international regulatory submissions, and clinical work in arteriovenous access for hemodialysis patients. Humacyte also reports quarterly financial results, business-development activity, financing actions and leadership changes tied to its transition from platform development to commercial-stage biotechnology operations.
Humacyte (HUMA) will feature its acellular tissue engineered vessel in five presentations at the VEITHsymposium on November 17–21, 2026.
Four presentations on November 18 will cover an infected-field reconstruction case, interim Phase 3 dialysis-access results in women, integrated outcomes from three Phase 3 trials and long-term explant evidence. A November 19 presentation will update Symvess clinical experience in military and civilian trauma settings. Humacyte plans to submit a supplemental biologics license application for arteriovenous access for hemodialysis in November. That use remains investigational.
Humacyte (Nasdaq: HUMA) reported third-quarter 2026 Symvess sales of $1.0 million, more than doubling the previous quarter as hospital adoption expanded. Sales rose 151% sequentially and compared with $0.7 million a year earlier. Hospitals ordering Symvess increased to 49 from 34 at the second-quarter end. October sales reached $0.8 million; Humacyte expects fourth-quarter sales to at least double third-quarter sales.
Quarterly net loss narrowed to $15.5 million from $17.5 million a year earlier. Operating cash use fell to $15.0 million from $23.9 million, with cash, cash equivalents and restricted cash of $64.9 million at September 30. Humacyte plans a November 2026 FDA application to add dialysis access as an approved use for its bioengineered vessel. It also initiated a Phase 2a study of its coronary tissue engineered vessel for coronary artery bypass grafting in November.
Humacyte (HUMA) has initiated a first-in-human Phase 2a study of its bioengineered coronary vessel for coronary artery bypass surgery. The study is open for enrollment and will evaluate safety and efficacy in ten adults with coronary artery disease. Vessel patency, or whether the graft remains open, will be assessed two months after implantation, with follow-up for up to three years. The FDA accepted the investigational new drug application in July 2026.
Presentations at the American Heart Association Scientific Sessions 2026 included preclinical results showing implanted vessels remained open for up to three months in sheep, with host cells populating the vessel walls. The coronary vessel remains investigational and is not approved for sale.
Humacyte (Nasdaq: HUMA) will feature its regenerative medicine technology in three presentations at the American Heart Association Scientific Sessions 2026.
The conference runs November 6–9 at McCormick Place in Chicago. Founder and CEO Laura Niklason will give an invited talk on vascular regeneration on November 7. Two other presentations will cover the first-in-human Phase 2a study design and preclinical results in pig and sheep models for the company’s coronary tissue engineered vessel, intended for coronary artery bypass grafting. Those presentations are scheduled for November 7 and November 8, respectively. The coronary vessel remains investigational and is not approved for sale by the FDA or any other regulatory agency.
Humacyte (HUMA) will release its third-quarter 2026 financial results and provide a business update on November 10, 2026. The results will cover the three months and nine months ended September 30, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to discuss the corporate and financial update.
Humacyte (Nasdaq: HUMA) received a new U.S. patent covering aspects of Symvess manufacturing, sterilization, storage and shipping, with protection into 2043.
U.S. Patent No. 12,742,144 also covers other bioengineered human tissues and complements existing patents and applications covering product design, composition and manufacturing methods. Symvess is an acellular tissue engineered vessel, a bioengineered blood vessel, that received FDA approval for extremity vascular trauma in December 2024. Humacyte plans to submit a supplemental biologics license application in 2026 seeking to add dialysis access as a second approved indication.
Humacyte (HUMA) reported that its Phase 3 V012 trial met the primary endpoint comparing bioengineered vessels with fistulas in female hemodialysis patients. The prespecified interim analysis covered the first 80 patients; enrollment stopped after the endpoint was met. Women receiving the acellular tissue engineered vessel (ATEV) averaged 220 catheter-free days in the first year, versus 129 with a surgically created arteriovenous fistula. Median time to functional dialysis access was 1.7 months versus 5.3 months.
Safety was comparable between groups. Dialysis access infections occurred at approximately 6 versus 23 per 100 patient-years, with no vessel-related infections in the ATEV group or spontaneous ruptures in either group. Humacyte targets an FDA application this quarter to expand the Symvess label to hemodialysis access, supported by V012 and two previously completed Phase 3 trials.
Humacyte (HUMA) reported a 44% third-quarter increase in hospitals that have ordered Symvess, its FDA-approved vessel for vascular trauma. The total rose from 34 hospitals at the end of the second quarter to 49 as of September 30, 2026. New hospital ordering activity increased sequentially each month of the third quarter.
Humacyte said the adoption trend shows potential to surpass its goal of adding 20 new hospitals by year-end and expects substantial growth through the remainder of 2026. Its revised commercial strategy began in the second quarter. Symvess is approved for adults with extremity arterial injury who need urgent restoration of blood flow to avoid imminent limb loss and cannot receive a graft made from their own vein. Further commercial updates are planned for the third-quarter earnings call.
Humacyte (HUMA) will present interim Phase 3 V012 trial results at an ASN Kidney Week late-breaking session on October 22, 2026. The randomized trial compares its acellular tissue engineered vessel (ATEV), a bioengineered blood vessel, with an arteriovenous fistula, a connection made from a patient's own blood vessels, for hemodialysis access in women with end-stage kidney disease. Prabir Roy-Chaudhury of the University of North Carolina at Chapel Hill will present the findings in Denver.
V012 results and two previously completed Phase 3 hemodialysis-access trials form the clinical foundation for a planned supplemental application to expand the Symvess label to include this use. Humacyte targets submission to the FDA this quarter. ATEV remains investigational for hemodialysis access; its existing FDA approval covers extremity vascular trauma.
Humacyte (HUMA) appointed Scott Coward and Paul Kuznik to its board of directors as it prepares a dialysis-access launch.
Coward joined the Audit Committee. He previously held executive and board roles at Exact Sciences, where he led the integration of Genomic Health following its acquisition. Kuznik joined the Commercial Committee. He previously led Bolton Medical and held U.S. and North American leadership roles at Terumo Aortic. Humacyte is expanding its ongoing Symvess launch and said it plans a U.S. commercial launch of its acellular tissue engineered vessel, or ATEV, for dialysis access. That use remains investigational and is not approved for sale by the FDA or any other regulator. ATEV is approved for extremity vascular trauma.